Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

SAB Biotherapeutics Q3 2026 Results: Net Loss of $22.3M

SAB Biotherapeutics reported a net loss of $22.3 million for the third quarter of 2026, compared to a net income of $45.4 million in the prior year period, primarily due to a significant decrease in the non-cash gain from the change in fair value of warrant liabilities. Operating expenses increased substantially to $25.9 million as the company ramped up research and development activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-22.345.4
EPS (diluted, $ a share)$-0.24$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SABS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

SAB Biotherapeutics, Inc.: key numbers

Share price
$3.00Close, Nov 16
Market cap
$270M
Shares outstanding
90.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from SAB Biotherapeutics, Inc.

All →
8:36 AM ET 8-K
Regulatory Approval

SAB Biotherapeutics Regulatory Approval

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.